Search results (55)
« Back to PublicationsImmunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective, single-centre, cohort study and analysis of transcriptomic predictors of response
Journal article
Drennan PG. et al, (2025), The Lancet Microbe, 6, 101045 - 101045
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG
Journal article
Marshall JL. et al, (2025), Nature Communications, 16
Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route
Journal article
Peralta Alvarez MP. et al, (2024), Vaccine, 42, 126444 - 126444
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Journal article
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
Inhaled aerosol viral-vectored vaccines against tuberculosis.
Journal article
Stylianou E. and Satti I., (2024), Current opinion in virology, 66
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
Journal article
Wajja A. et al, (2024), The Lancet Infectious Diseases, 24, 285 - 296
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
Journal article
Wajja A. et al, (2024), The Lancet Infectious Diseases, 24, e78 - e79
Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
Journal article
Satti I. et al, (2022), Nature Communications, 13
Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.
Journal article
Wilkie M. et al, (2022), Scientific reports, 12
Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
Journal article
Bitencourt J. et al, (2022), Frontiers in Immunology, 12
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults
Journal article
Riste M. et al, (2021), Vaccines, 9, 396 - 396
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
Journal article
Tanner R. et al, (2021), F1000Research, 10, 257 - 257
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
Journal article
Tanner R. et al, (2021), npj Vaccines, 6
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
Journal article
Tanner R. et al, (2020), Frontiers in Immunology, 10
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
Journal article
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789